IQVIA™ Real-World Insights Bibliography

High?Expenditure Disease in the EU?28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?
Author(s): Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck
Affiliations(s): Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium
Publication(s):  PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4
Document Type(s): Article,
Countries: Europe,
Click here for the abstract
C:
Y:
Diabetes, Health economics, Oncology,
2021
  L:
A:
English
Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review,
  Add to report
 
 
How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools
Author(s): Elvira D'Andrea, Lydia Vinals, Elisabetta Patorno, Jessica M. Franklin, Dimitri Bennett , Joan A. Largent, Daniela C. Moga, Hongbo Yuan, Xuerong Wen, Andrew R. Zullo, Thomas P. A. Debray, Grammati Sarri
Affiliations(s): D'Andrea: Harvard; Largent: IQVIA
Publication(s):  http://orcid.org/0000-0002-5263-3964PubMed articles
Document Type(s): Article,
Countries: Europe, USA,
Click here for the abstract
C:
Y:
Methodology,
2021
  L:
A:
English
Literature Review,
  Add to report
 
 
Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making
Author(s): Grammati Sarri 1, Elisabetta Patorno 2, Hongbo Yuan 3, Jianfei Jeff Guo 4, Dimitri Bennett 5, Xuerong Wen 6, Andrew R Zullo 7, Joan Largent 8, Mary Panaccio 9, Mugdha Gokhale 10, Daniela Claudia Moga 11, M Sanni Ali 12 13 14, Thomas P A Debray 15 16
Affiliations(s): 1Real World Evidence Sciences, Visible Analytics Ltd, Oxford, UK grammati.sarri@visibleanalytics.co.uk. 2Division of Pharmacoepidemiology and Pharmacoeconomics, Dept. of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 3Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, Ontario, Canada. 4Department of Pharmacy Practice & Administrative Sciences, University of Cincinnati College of Pharmacy, Cincinnati, Ohio, USA. 5Takeda, Cambridge, Massachusetts, USA. 6Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA. 7Health Services, Policy, and Practice, Brown University, Providence, Rhode Island, USA. 8Real-World Solutions, IQVIA, California, Colorado, USA. 9Epidemiology and Outcomes Research, Research Outcomes Innovations LLC, New York City, New York, USA. 10GlaxoSmithKline USA, Philadelphia, Pennsylvania, USA. 11University of Kentucky, Department of Pharmacy Practice and Science, Lexington, Kentucky, USA. 12NDORMS, Center for Statistics in Medicine, University of Oxford, Oxford, UK. 13Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine (LSHTM), London, UK. 14Department of Public Heath, Environments and Society, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine (LSHTM), London, UK. 15Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands. 16Smart Data Analysis and Statistics, Utrecht, The Netherlands.
Publication(s):  PMID: 33298465 DOI: 10.1136/bmjebm-2020-111493
Document Type(s): Article,
Countries: Europe, USA,
Click here for the abstract
C:
Y:
Methodology,
2021
  L:
A:
English
Literature Review,
  Add to report
 
 
Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE
Author(s): P. Escribano (1), S. Gaine (2), P. Biedermann (3), A. Muller (3), M. Valge (4), T. Lange (5), S. Söderberg (6)
Affiliations(s): 1 Pulmonary Hypertension Unit, Cardiology Department, CIBERCV, Hospital 12 de Octubre, Madrid, Spain 2 National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland 3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland 4 StatFinn Estonia OÜ, Tartu, Estonia (now IQVIA) 5 University Medical Center Regensburg, Regensburg, Germany 6 Department of Public Health and Clinical Medicine, Cardiology and Heart Centre, Umeå University, Umeå, Sweden
Publication(s):  JO - The Journal of Heart and Lung Transplantation VL - 40 IS - 4, Supplement SP - S109 PY - 2021 DA - 2021/04/01/ SN - 1053-2498
Document Type(s): Abstract,
Countries: Canada, Europe,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2021
  L:
A:
English
Epidemiological study, Observational study,
  Add to report
 
 
A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe.
Author(s): Jouaville LS, Paul T, Almas MF
Affiliations(s): IQVIA
Publication(s):  Pharmacoepidemiol Drug Saf. 2021 Sep;30(9):1143-1152. doi: 10.1002/pds.5301.
Document Type(s): Article,
Countries: Europe,
Click here for the abstract
C:
Y:
Guidelines, Methodology, Risk Management & REMS,
2021
  L:
A:
English
Literature Review,
  Add to report
 
 
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study
Author(s): Gerard E.Franciscoa; Daniel S.Bandari; Ganesh Bavikattec; Wolfgang H.Jost; Emily McCusker; Joan Largent; Alekse Zuzek; Alberto Esquenazi
Affiliations(s): a The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA b Multiple Sclerosis Center of California & Research Group, Newport Beach, CA, USA c The Walton Centre, Liverpool, UK d University of Freiburg, Department of Neurology, Freiburg im Breisgau, Germany e Parkinson-Klinik Ortenau, Wolfach, Germany f Allergan, an AbbVie Company, Irvine, CA, USA g IQVIA Real-World Evidence Solutions, Cambridge, MA, USA h MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA
Publication(s):  PM R . 2020 Jan 17. doi: 10.1002/pmrj.12328.
PMID: 31953896 DOI: 10.1002/pmrj.12328
Document Type(s): Article,
Countries: Asia Pacific, Europe, USA,
Click here for the abstract
C:
Y:
Drug Utlization Study, Medication compliance,
2020
  L:
A:
English
Methodology, Observational study,
  Add to report
 
 
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study
Author(s): Gerard E Francisco 1, Daniel S Bandari 2, Ganesh Bavikatte 3, Wolfgang H Jost 4 5, Emily McCusker 6, Joan Largent 7, Aleksej Zuzek 6, Alberto Esquenazi 8
Affiliations(s): 1The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA. 2Multiple Sclerosis Center of California & Research Group, Newport Beach, CA, USA. 3The Walton Centre, Liverpool, UK. 4University of Freiburg, Department of Neurology, Freiburg im Breisgau, Germany. 5Parkinson-Klinik Ortenau, Wolfach, Germany. 6Allergan, an AbbVie Company, Irvine, CA, USA. 7IQVIA Real-World Evidence Solutions, Cambridge, MA, USA. 8MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA.
Publication(s):  PMID: 32875289 PMCID: PMC7452133 DOI: 10.1016/j.toxcx.2020.100040
Document Type(s): Article,
Countries: Europe, USA,
Click here for the abstract
C:
Y:
Neurological disorders,
2020
  L:
A:
English
Epidemiological study, Observational study,
  Add to report
 
 
Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Clinician- and Patient-Reported Satisfaction: Long-Term Observational Results from the ASPIRE Study
Author(s): Gerard E Francisco 1, Wolfgang H Jost 2, Ganesh Bavikatte 3, Daniel S Bandari 4, Simon F T Tang 5, Michael C Munin 6, Joan Largent 7, Aubrey M Adams 8, Aleksej Zuzek 8, Alberto Esquenazi 9
Affiliations(s): 1The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX. 2Department of Neurology, University of Freiburg, Freiburg im Breisgau, Germany. 3The Walton Centre, Liverpool, UK. 4Multiple Sclerosis Center of California & Research Group, Newport Beach, CA. 5Department of Physical Medicine and Rehabilitation, Lotung Poh-Ai Hospital, Yilan, Taiwan. 6Department of Physical Medicine and Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, PA. 7IQVIA Real-World Evidence Solutions, Cambridge, MA. 8Allergan plc, Irvine, CA. 9MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA.
Publication(s):  PMID: 31953896 PMCID: PMC7687094 DOI: 10.1002/pmrj.12328
Document Type(s): Article,
Countries: Asia Pacific, Europe, USA,
Click here for the abstract
C:
Y:
Neurological disorders,
2020
  L:
A:
English
Epidemiological study, Observational study,
  Add to report
 
 
Interventional or Non-Interventional? Analyzing the Differences Between Clinical Studies Using Medicines in the European Union
Author(s): Tiago Silva, MSc; Alexandra Parnell, MSc; Christopher Bamford, PhD; Catherine Paulen, PharmD; Simona Francisconi, MSc; Jaclyn Bosco, PhD, MPH; Louise Parmenter, PhD, MSc
Affiliations(s): 
Publication(s):  Clinical Researcher February 2020; Volume 34, Issue 2
Document Type(s): Article, Online article,
Countries: Europe,
Click here for the abstract
C:
Y:
Clinical practice,
2020
  L:
A:
English
Population Based Study, Retrospective database analysis,
  Add to report
 
 
Outcome measurement in pregnancy exposure registries: A preliminary review of publicly available resources
Author(s): Suzanne N. Landi, Jessica R. Probst , Katherine Lee, , Elsa García Hernández , Kristen Hahn
Affiliations(s): IQVIA, Durham, NC NoviSci Inc., Durham, NC
Publication(s): 
Document Type(s): 
Countries: Europe, USA,
C:
Y:
Pregnancy,
2019
  L:
A:
English
Population Based Study, Review,
  Add to report
 
 
 1 of 6 Next Page Last Page